Paul Tudor Jones's MDGL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 926 shares of Madrigal Pharmaceuticals, Inc. (MDGL) worth $424,719, representing 0.00% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in MDGL, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 7,069 shares. Largest reduction occurred in Q2 2023, reducing 9,610 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Madrigal Pharmaceuticals (MDGL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Madrigal Pharmaceuticals (MDGL) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2019 | +5,589 | New Buy | 5,589 | $91.07 |
| Q1 2020 | -5,589 | Sold Out | 5,589 | $0.00 |
| Q4 2021 | +8,536 | New Buy | 8,536 | $84.70 |
| Q1 2022 | -8,536 | Sold Out | 8,536 | $0.00 |
| Q2 2022 | +7,817 | New Buy | 7,817 | $71.64 |
| Q3 2022 | +11 | Add 0.14% | 7,828 | $65.02 |
| Q4 2022 | +617 | Add 7.88% | 8,445 | $0.29 |
| Q1 2023 | +4,384 | Add 51.91% | 12,829 | $0.24 |
| Q2 2023 | -9,610 | Reduce 74.91% | 3,219 | $231.00 |
| Q3 2023 | +1,473 | Add 45.76% | 4,692 | $146.04 |
| Q4 2023 | -4,692 | Sold Out | 4,692 | $0.00 |
| Q1 2024 | +3,258 | New Buy | 3,258 | $267.04 |
| Q2 2024 | -3,258 | Sold Out | 3,258 | $0.00 |
| Q4 2024 | +10,327 | New Buy | 10,327 | $308.57 |
| Q1 2025 | -10,327 | Sold Out | 10,327 | $0.00 |
| Q3 2025 | +926 | New Buy | 926 | $458.66 |
Paul Tudor Jones's Madrigal Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Madrigal Pharmaceuticals, Inc. (MDGL) in Q4 2019, acquiring 5,589 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Madrigal Pharmaceuticals, Inc. (MDGL) for 24 quarters since Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Madrigal Pharmaceuticals, Inc. (MDGL) was in Q4 2024, adding 10,327 shares worth $3.19 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 926 shares of Madrigal Pharmaceuticals, Inc. (MDGL), valued at approximately $424,719. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Madrigal Pharmaceuticals, Inc. (MDGL) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Madrigal Pharmaceuticals, Inc. (MDGL) was 12,829 shares, as reported at the end of Q1 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.